Source: Virtual Congress 2021 – COVID-19 and acute respiratory failure



Rating:

Share or cite this content

Citations should be made in the following way:
A. Eldien Thabet Hassan (Assiut, Egypt), A. Abdelmoniem (Assiut, Egypt), M. Mohamed (Assiut, Egypt), A. Elsherif (Al azhar, Egypt), S. Kasim (Assiut, Egypt). Challenges in steroids and anicoagulants in severe COVID-19 pneumonia. 911

Member's Comments

No comment yet.

Related content which might interest you: Systemic corticosteroid for treating severe community-acquired pneumonia Source: International Congress 2015 – Advances in pneumonia management, COPD therapy and lung nodule evaluation Year: 2015 Critical illness-related corticosteroid insufficiency and community-acquired pneumonia: back to the future! Source: Eur Respir J 2008; 31: 1150-1152 Year: 2008 Corticosteroids in severe pneumonia Source: Eur Respir J 2008; 32: 259-264 Year: 2008 Are corticosteroids useful in community-acquired pneumonia? Source: Annual Congress 2006 - Evaluation of risk factors in community-acquired pneumonia Year: 2006 Low-dose corticosteroids during severe community-acquired pneumonia: end of the story Source: Eur Respir J 2015; 45: 305-307 Year: 2015 Treatment failure of severe and ventilator-associated pneumonia Source: Annual Congress 2012 - PG17 Clinical failure of treatment of respiratory infections Year: 2012 Challenges in the management of hospital-acquired pneumonia including ventilator-associated pneumonia Source: ERS Course 2018 - Respiratory Infections Year: 2018 Low-dose corticosteroid use and mortality in severe community-acquired pneumonia patients Source: Eur Respir J 2015; 45: 463-472 Year: 2015 Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia Source: Eur Respir J 2009; 33: 153-159 Year: 2009 Benefits of co-administration of macrolides and glucocorticosteroids in the treatment of severe community acquired pneumonia Source: International Congress 2016 – Community-acquired pneumonia: update on prognostic factors and therapeutic strategies Year: 2016 Update on preventing and managing hospital-acquired and ventilatory-associated pneumonia Source: International Congress 2019 – State of the art session: Respiratory infections Year: 2019 Effects of systemic steroids in patients with severe community-acquired pneumonia Source: Eur Respir J 2007; 30: 951-956 Year: 2007 Treatment of severe community-acquired pneumonia: new horizons Source: International Congress 2014 – Advances in managing acute respiratory failure Year: 2014 Effect of corticoids on the clinical course and outcome of severe community-acquired pneumonia Source: Annual Congress 2004 - SARS and other lower respiratory tract infections Year: 2004 Whether there are pharmacoeconomic and other advantages of using procalcitonin-guide antibacterial treatment in patients with severe community-acquired pneumonia in developing countries? Source: International Congress 2015 – Pneumonia: determinants of clinical outcomes and potential strategies to improve its management Year: 2015 Impact of inhaled corticosteroid use on outcome in COPD patients admitted with pneumonia Source: Eur Respir J 2011; 37: 36-41 Year: 2011 is hypercapnia associated with severe forms of community-acquired pneumonia? Source: Virtual Congress 2020 – Lower respiratory tract infections in clinical practice Year: 2020 Adjunctive systemic corticosteroid treatment in hospitalized patients with community-acquired pneumonia Source: Annual Congress 2012 - Anti-infective treatment and resistance in respiratory infections Year: 2012 Relationship between the use of inhaled steroids and early outcomes in community-acquired pneumonia Source: International Congress 2016 – Community-acquired pneumonia: from prevention to treatment Year: 2016 Acute bronchiolitis in hospitalised patients: inappropriate use of corticosteroids Source: Eur Respir J 2005; 26: Suppl. 49, 29s Year: 2005